Ankit Mahadevia

Ankit Mahadevia is a principal at Atlas Venture, which he joined in 2008. Previously, Ankit worked on product and business development with the founding team at Arcion Therapeutics, a specialty pharmaceutical company developing topical applications in neuropathic pain. Before Arcion Therapeutics, he held positions in Business Development at Genentech, and at Vanda Pharmaceuticals, a specialty pharmaceutical company focused on targeted therapies in psychiatry. He also served clients in the health services sector at McKinsey and Company. Ankit also has previous experience as a Consultant at Monitor Group, where he supported clients in the biotechnology and medical device industries on strategy, marketing, and business development. He held roles in health policy at the Senate Health, Education, Labor, and Pensions Committee, the U.S. Government Accountability Office, and the Mexican Institute of Social Security (IMSS).

Ankit completed his MD at Johns Hopkins University School of Medicine, and his MBA at the Wharton School at the University of Pennsylvania. He graduated summa cum laude with a Bachelor of Arts in Economics and Biology from Northwestern University. During his medical training Ankit published research in glaucoma therapy and neurovascular interventions. Ankit serves on the board of Lumavita AG and Fibrex Medical and is a board observer at Resolvyx Pharmaceuticals, Nimbus Discovery, and Molecular Biometrics. He also serves on the board of the Johns Hopkins Technology Alliance and as a reviewer for the National Cancer Institute SBIR Bridge Awards.